As morbidly obese patients are prone to surgical site infections, adequate blood and subcutaneous tissue concentrations of prophylactic antibiotic agents during surgery are imperative. In this study, we evaluated cefazolin subcutaneous adipose tissue distribu tion in morbidly obese and nonobese patients, thereby quantifying the influence of morbid obesity on cefazolin pharmacokinetics and enabling Monte Carlo simulations for subsequent dose adjustments.
AbstrACt objectives
As morbidly obese patients are prone to surgical site infections, adequate blood and subcutaneous tissue concentrations of prophylactic antibiotic agents during surgery are imperative. In this study, we evaluated cefazolin subcutaneous adipose tissue distribu tion in morbidly obese and nonobese patients, thereby quantifying the influence of morbid obesity on cefazolin pharmacokinetics and enabling Monte Carlo simulations for subsequent dose adjustments.
Methods
Nine morbidly obese patients (body mass index (BMI) of 47 ± 6 kg/m 2 ) of which eight were evaluable, and seven nonobese patients (BMI of 28 ± 3 kg/m 2 ) received cefazolin 2 gram intravenously before surgery (NCT01309152). Using microdialysis, interstitial space fluid (ISF) samples of subcutaneous adipose tissue were collected together with total and unbound plasma cefazolin samples until 240 min after dosing. Using NONMEM, population pharmacokinetic modelling, covariate analysis and Monte Carlo simulations were performed.
results
The unbound (free) cefazolin ISF penetration ratio (fAUC tissue /fAUC plasma) was 0.70 (0.68 0.83) in morbidly obese patients versus 1.02 (0.851.41) in nonobese patients (p<0.05). A twocompartment model with saturable protein binding was identified in which the central volume of distribution and cefazolin distribution from the central compartment to the ISF compartment proved dependent on body weight (p<0.001 and p<0.01, re spectively). Monte Carlo simulations showed reduced probability of target attainment for morbidly obese versus nonobese patients for MIC values of 2 and 4 mg/L.
Conclusions
This study shows that cefazolin tissue distribution is lower in morbidly obese patients and reduces with increasing body weight, and that dose adjustments are required in this patient group.
IntroduCtIon
The prevalence of obesity (body mass index (BMI) >30kg/m 2 ) and morbid obesity (BMI >40kg/m 2 ) is increasing worldwide. European obesity prevalence rates range be tween 4 and 37%, while in the USA 36% of the population is obese and 5% is morbidly obese 12 . Obesity and morbid obesity are considered an independent risk factor for postoperative surgical site infection 35 . To prevent surgical site infection, for surgery above or including the duodenum, cefazolin is the prophylactic agent of choice 6 . As a target site for prophylactic antibiotics, distribution to the interstitial space fluid (ISF) of the subcutaneous adipose tissue should be considered. At least between opening and closure of the skin, the unbound cefazolin concentration in the ISF should be above the minimal inhibitory concentration (MIC) for the target microorganisms 7 .
Despite extensive use of cefazolin as antibiotic prophylaxis, there is limited data available from controlled clinical trials in morbidly obese patients. Previous studies in morbidly obese patients have so far only reported cefazolin concentrations in biopsy samples taken from fat tissue, but these samples inadequately reflect unbound cefazolin concentrations in the ISF as biopsy samples provide average concentrations for com bined intra and extracellular compartments 810 . Furthermore, cefazolin is highly protein bound and thus only a relatively small part of the concentration is available for antibiotic effect. To date, clinical microdialysis is the only sampling technique that allows measure ment of extracellular, unbound (i.e. active) drug concentrations in virtually any tissue and is hence suitable for measuring unbound cefazolin concentrations in the ISF of the subcutaneous adipose tissue 1112 .
Therefore, the objective of this study is to measure and compare unbound cefazolin concentrations in the ISF of the subcutaneous adipose tissue of morbidly obese and nonobese patients, using a microdialysis technique. The results were used to quantify the influence of overweight on cefazolin pharmacokinetics by developing a model for total and unbound plasma cefazolin and unbound cefazolin in the ISF, which can be used for Monte Carlo simulations and subsequent dose adjustments.
MAterIAls And Methods

Patients
Morbidly obese patients (BMI>40 kg/m 2 ) undergoing laparoscopic gastric bypass sur gery and nonobese patients (BMI 2030 kg/m 2 at the inclusion of the study) undergoing laparoscopic Toupet fundoplication surgery were considered for inclusion in the study. Patients were excluded from the study if they were pregnant, breastfeeding, suffered from renal insufficiency, had a known allergy to cefazolin or had an ejection fraction below 35%. Before participation, all patients gave written informed consent. Laboratory values for evaluation of renal function were available after inclusion of the patient in the study. The study was approved by the local human research and ethics committee of Nieuwegein (VCMO), The Netherlands (NL33065.100.10) and was conducted according to the principles of the Declaration of Helsinki (version 22102008) and in accordance with the Medical Research Involving Human Subjects Act (WMO) of The Netherlands.
study design and procedure
This was a prospective observational study (NCT01309152). For anesthesia, all patients received propofol/remifentanil and received a 2 gram intravenous (iv) bolus injection of cefazolin at 15.6 ± 4.3 (range of 824) minutes before start of surgery. Up to 4 hours after the cefazolin dose, blood and subcutaneous ISF samples were collected. Arterial blood samples were drawn for the measurement of total and unbound plasma cefazolin, while subcutaneous adipose ISF samples were collected using clinical microdialysis. Three hours before surgery a microdialysis probe (CMA60, Microdialysis, Solna, Sweden) was inserted in the subcutaneous tissue of the right or left side of the abdomen. After a 20 minute baseline perfusion period with blank lactated Ringer's, the catheter was per fused with 5 mg/L cefazolin in lactated Ringer's solution for 40 minutes for calibration of the microdialysis catheter using the retrodialysis technique 13 . A sample was collected during the last 20 minutes of the retrodialysis procedure to calculate the recovery:
where C dialysate is the cefazolin concentration in the dialysate leaving the probe and C perfusate is the cefazolin concentration in the perfusion fluid entering the probe 14 . The microdialysis recovery ratio was 27.1% ± 8.0 for morbidly obese patients (n=9) and 27.4% ± 13.4 for nonobese patients (n=7). To prevent cefazolin carry over from the ret rodialysis procedure to the actual samples after the cefazolin iv dose, the microdialysis catheter was washed out with blank lactated Ringer's solution for at least 2 hours after calibration. At the time of cefazolin iv administration, microdialysis sample collection was started and samples were collected every 20 minutes until 4 hours after the dose. As a result, each collected microdialysis sample represented the average concentrations over a time span of 20 minutes. Throughout the whole procedure the microdialysis flow rate was kept at 2 μL/minute. In nonobese patients, to determine total and unbound cefazolin concentrations in plasma, arterial blood samples were taken before and at 5, 10, 30, 60, 120 and 240 minutes after the cefazolin iv dose. In morbidly obese patients, arterial blood samples for total cefazolin concentrations in plasma, were taken before and at 10, 120 and 240 minutes after dose and samples for unbound plasma cefazolin were collected at 5, 10, 30, 60, 120 and 240 minutes after the cefazolin iv dose. Blood samples were centrifuged at 3000 RPM (1500 g) for 15 minutes at 4ºC and plasma was collected. Both plasma and microdialysis samples were stored at 80ºC until analysis.
drug assay
Total and unbound cefazolin concentrations in plasma were determined using a vali dated reversedphase HPLC method with UV detection at 254 nm (total plasma cefazolin concentrations) and 272 nm (unbound cefazolin plasma and microdialysis concentra tions), based on a modification of the method of Kamani et al., described previously 1516 . In brief, a LiChrospher 100 RP18 5 μm column was used for separation and the mobile phase, a mixture of 0.01 M acetic acid, acetonitrile and methanol (87.4/12/0.6, v/v/v), was eluted at 0.71 mL/min. Microdialysis samples were injected directly onto the HPLC column. The limit of detection and limit of quantification for unbound cefazolin concen trations in plasma and cefazolin in lactated Ringer's (microdialysis samples) were 0.3 and 1 mg/L, respectively. For total cefazolin concentrations in plasma, the limit of detection and lower limit of quantification were 1 mg/L and 5 mg/L, respectively.
statistical analysis
The student's t-test was applied to test differences in demographic variables between the study groups. For cefazolin concentrations the nonparametric MannWhitney test was applied to test statistical differences between the groups. The observed area under the timeconcentration curve from 0 to 4 hours after the dose (AUC 04 h ) was calculated for each patient separately, using the linear trapezoidal rule 17 . Outlying data was evaluated using Grubb's test for detecting outliers 18 . These statistical analyses were performed using IBM SPSS software, version 19.0.0.
Population pharmacokinetic analysis and internal validation
The population pharmacokinetic analysis was performed by means of nonlinear mixed effects modelling using NONMEM (version 6.2, release 1.1; GloboMax LLC, Hanover, MD, USA) 19 . SPlus (version 6.2; Insightful Software, Seattle, WA, USA) with NM.SP.interface© version 05.03.02 (LAP&P, Leiden, The Netherlands) was used to visualize the data. Dis crimination between different models was made by comparison of the objective func tion value (OFV, i.e. 2 log likelihood (2LL)). A p value <0.05, representing a decrease of 3.84 in the OFV, was considered statistically significant. In addition, goodnessoffit plots (observed versus individualpredicted concentrations, observed versus population predicted concentrations, conditional weighted residuals versus time and conditional weighted residuals versus populationpredicted concentrations plots) were used for di agnostic purposes. Furthermore, the confidence interval of the parameter estimates, the correlation matrix and visual improvement of the individual plots were used to evaluate the model. The internal validity of the population pharmacokinetic model was assessed by the bootstrap resampling method using 250 replicates and normalized prediction distribution errors (NPDEs) 20 . Parameters obtained with the bootstrap replicates were compared with the estimates obtained from the original dataset. NPDE plots were checked for normal distribution characteristics and trends in the data errors.
structural model
To describe all cefazolin concentrations (total plasma, unbound plasma and unbound subcutaneous ISF concentrations) a twocompartment model (ADVAN 6) was used. The model was parameterized in terms of the volume of distribution of the central compartment (V1), volume of distribution of the subcutaneous ISF compartment (V2), intercompartmental clearance from the central compartment to the subcutaneous compartment (Q), clearance from the central compartment (CL) and the fraction un bound (FU), as depicted in Figure 1 . The fraction unbound (FU) was modelled according to equation 2,
where B max is the maximal binding capacity, C total is the total cefazolin plasma concentra tions and K d is the dissociation constant for cefazolin binding to albumin.
Intercompartmental clearance between the central and subcutaneous ISF compart ment (Q) was equated to CL as both values were very similar and this improved good ness of fit plots of the nonobese patients (p<0.01; decrease of 20 in Objective Function Value, (20 ΔOFV)). 
Where θ mean is the population mean, and η i is a random variable for the ith individual with a mean of zero and variance of ω 2 , assuming lognormal distribution in the population. The residual variability, resulting from assay errors, model misspecifications and other unexplained sources, was best described with a proportional error model for total and unbound cefazolin plasma concentrations and a separate proportional error for unbound subcutaneous ISF cefazolin concentrations. The jth observed cefazolin concentration of the ith individual (Y ij ) is described by equation 4:
Where C pred , ij is the population predicted cefazolin concentration of the ith individual at the jth time, and ε ij is a random variable with a mean of zero and variance of σ 2 .
Covariate analysis
Covariates were plotted independently against the individual eta (η) estimates of phar macokinetic parameters to visualize potential relations. The following covariates were tested: total body weight (TBW), BMI, lean body weight (LBW) 21 , sex, obesity and age. Covariates (except for sex and obesity) were tested using linear and allometric equations (equation 5 and 6):
where P i and P p represent individual and population parameter estimates, respectively; COV represents the covariate; COV median represents the median value of the covariate for the population; X represents the exponential scaling factor, which was fixed at 1 for a linear function or an estimated value for a power function; and Y represents a correlation factor between the population pharmacokinetic parameters and the change in covariate value. The binary covariates sex and obesity were tested using the following equation:
where P i and P p represent individual and population parameter estimate, Z the esti mated factor of increase or decrease for the patients subgroup with COV equaling 1. Potential covariates were separately entered into the model and statistically tested by use of the OFV and, if applicable, the 95% confidence interval of the additional pa rameter. In addition, if applicable, we evaluated whether the interindividual variability in the parameter concerned reduced in value upon inclusion of the covariate on the parameter. When more than one significant covariate for the simple model was found, the covariateadjusted model with the largest decrease in the OFV was chosen as a basis to sequentially explore the influence of additional covariates with the use of the same criteria. Finally, after forward inclusion (p<0.05), a backward exclusion procedure was applied to justify the inclusion of a covariate (p<0.01). The choice of the covariate model was further evaluated as discussed above (in Population pharmacokinetic analysis and internal validation).
Monte Carlo simulations
Monte Carlo simulations based on body weight and age distributions of the original populations, were performed to simulate cefazolin concentrationtime profiles of 5000 morbidly obese patients and 5000 nonobese patients. In these simulations, the unbound (free) area under the curve ratios (fAUC tissue /fAUC plasma ) were calculated by al lowing the unbound plasma and subcutaneous concentrations to accumulate over time in hypothetical compartments.
results
Patients and data
Nine morbidly obese patients with a mean body weight of 141.4 ± 22 kg (range 107 -175) and 7 nonobese patients with a mean body weight of 86.2 ± 13 kg (range 72 109) participated in the study. Immediately after inclusion, one morbidly obese patient was excluded from the study because of an estimated glomerular filtration rate (GFR) of 60 mL/min instead of an estimated GFR >60 mL/min (ID 3), which was noticed after inclusion. Furthermore, ISF measurements from another morbidly obese patient were excluded from the analysis because the unbound area under the ISF curve (fAUC ISF 04 h ) and fAUC tissue /fAUC plasma ratio of this patient were strongly deviating and outlying based on the Grubb's test for detecting outliers 18 (p<0.05 and p<0.01, respectively (ID 2)). Patient characteristics of 8 morbidly obese and 7 nonobese patients are summarized in Table 1 . Data are mean ± standard deviation and range (minimummaximum). 
Population pharmacokinetic model and validation
A twocompartment pharmacokinetic model with saturable plasma protein binding best described the data (Figure 1, equation 2) . Using this structural model without covariates, total and unbound plasma cefazolin concentrations in both patient groups were well described, while individual and populationpredicted subcutaneous ISF concentrations were overpredicted in morbidly obese patients and underpredicted in the nonobese patients. Exploration and testing of covariates for V1, V2, Q, CL and B max showed im provements of fit for unbound cefazolin plasma concentrations; however, the observed trend for subcutaneous ISF cefazolin concentrations (overprediction for morbidly obese patients, underprediction for nonobese patients) could not be explained by any of the preliminary covariates on any of the parameters. Therefore, potential nonlinearity in cefazolin distribution from the central (V1) to subcutaneous ISF compartment (V2) was evaluated by adding a power function (γ) on the cefazolin amount (concentration) in the central compartment (A 1 ):
where A x stands for the amount of cefazolin in the xth compartment, FU is the fraction unbound (equation 2) and k 12 is a rate constant between compartments 1 and 2. Although no nonlinearity was identified because gamma was not found to differ signif icantly from 1, addition of interindividual variability on gamma strongly improved the goodness of fit of the subcutaneous ISF concentrations (p<0.001, 124 ΔOFV). Parameter values of the simple model without covariates are summarized in Table 2 .
With the extended model, a covariate analysis was performed and exploratory plots of covariates against individual post hoc parameter estimates of the simple model showed potential relationships for different body size descriptors (TBW, BMI and LBW) with volume of distribution (V1) and the γ factor, for age and TBW with clearance and for LBW with B max . After forward inclusion and backward deletion of covariates in the model, TBW proved to be the strongest predictor of interindividual variability of both central volume of distribution (p<0.001, 77 ΔOFV) and γ representing cefazolin distribution to subcutaneous tissue (p<0.01, 10 ΔOFV). For clearance, age significantly improved the model (p<0.01, 10 ΔOFV). Finally, LBW seemed to be a covariate for B max ; however, this covariate relationship was not included in the final model due to limited statistical significance (p>0.01, 6 ΔOFV) in the backward deletion step. Parameters estimates of the final covariate model are summarized in Table 2 . The table shows that implementation of the covariates age and total bodyweight on the parameters γ and clearance in the final model indeed explained variability in these parameters (decrease in interindividual variability in γ and clearance of 1.1 % and 8.6 %). Figure 3 shows observed versus population predicted cefazolin concentrations in the ISF of subcutaneous tissue (b), unbound plasma (d) and total plasma (f ) for morbidly obese and nonobese patients of the final model. The figure shows that there was no remaining bias in any of the plots between data from morbidly obese or non obese patients, except for a slight overestimation of the lower subcutaneous concentrations in some of the morbidly obese patients (figure 3b). The final covariate model was validated using bootstrap analysis confirming the re sults ( Table 2 ) and normalized predictions distributions errors analysis which indicated normal distributions of errors ( Figure S1 , available as Supplementary data at JAC Online and at the end of this Chapter).
Monte Carlo simulations
The final covariate model was used to simulate concentrationtime profiles of subcuta neous ISF and unbound plasma cefazolin in 5000 morbidly obese and 5000 nonobese patients. The probability for the patient groups remaining above a certain minimal inhibi tory concentration (MIC) 120, 180 and 240 minutes after a 2 gram iv dose are summarized in Table 3 . Figure 4 illustrates the probability of target attainment that can be expected for unbound cefazolin concentrations in the ISF of morbidly obese versus nonobese pa tients. It shows that the probabilities of target attainment of unbound cefazolin plasma concentrations are more similar in both patient groups. The mean simulated unbound cefazolin ISF penetration ratio, expressed as fAUC tissue /fAUC plasma , for morbidly obese pa tients was 0.85 ± 0.19 in morbidly obese patients and 1.14 ± 0.27 in nonobese patients.
dIsCussIon
This study aimed to measure and compare unbound cefazolin concentrations in the ISF of the subcutaneous adipose tissue of morbidly obese and nonobese patients and to quantify the influence of overweight and other covariates on cefazolin pharmacokinet ics. Using clinical microdialysis, it was found that unbound cefazolin subcutaneous tis sue penetration was lower in morbidly obese compared with nonobese patients. When analyzing these results in a population analysis, a two compartment population phar macokinetic model with saturable protein binding was found to adequately describe all measured cefazolin concentrations. The covariate analysis showed that central volume of distribution increased linearly with body weight and that cefazolin distribution from the central to subcutaneous compartment decreased with body weight in a nonlinear manner.
Unbound cefazolin concentrations in the ISF of the subcutaneous adipose tissue have not been reported previously for morbidly obese patients, despite the fact that reduced tissue penetration of antibiotic agents in morbidly obese versus nonobese patients has been reported before. Cefoxitin, which is a cephalosporin class antibiotic agent like ce fazolin, also showed a reduced tissue penetration in morbidly obese versus nonobese patients (0.08 ± 0.07 versus 0.37 ± 0.26, p<0.05), although this AUC ratio was calculated using total cefoxitin plasma concentrations instead of unbound plasma concentrations, while cefoxitin is ~34% protein bound 22 . Also, in that study morbidly obese patients were compared with mostly healthy volunteers who did not undergo surgery 22 . Further more, reduced tissue penetration in morbidly obese patients was found for ciprofloxacin (0.45 ± 0.27 versus 0.82 ± 0.36, p<0.01), though in the study by Hollenstein et al. protein binding was not considered either 23 . The lower drug penetration into the subcutaneous adipose tissue of morbidly obese patients found in these studies and in the present study may potentially be explained by lower subcutaneous adipose blood flow. It has been shown before that subcutaneous adipose tissue blood flow in obese and morbidly obese patients is lower than in healthy control subjects 2425 . Additionally, Joukhadar et al. found in healthy volunteers that enhanced subcutaneous blood flow resulted in higher subcutaneous ciprofloxacin concentrations 26 . Therefore, we think that the lower subcutaneous adipose tissue penetration of cefazolin in morbidly obese patients after a single dose may be explained by lower subcutaneous adipose tissue blood flow.
In the population pharmacokinetic model the difference in subcutaneous ISF ce fazolin concentrations in morbidly obese and nonobese patients was not adequately described by TBW on central volume of distribution (V1) alone or by additional covari ates for intercompartmental clearance (Q) or the subcutaneous ISF compartment (V2). However, the introduction of interindividual variability on a γ factor (equation 8) on the distribution of cefazolin amount from the central (V1) to the subcutaneous compart ment (V2) was able to improve the goodness of fit of the subcutaneous cefazolin data for both patient groups. Despite the small absolute difference in γ between a morbidly obese and nonobese patient, it strongly impacts on cefazolin distribution from the central to the subcutaneous compartment: where a nonobese individual of 75 kg with a corresponding γ value of 1.02 transports 300 mg unbound cefazolin/minute from the central to subcutaneous compartment, a morbidly obese patient of 145 kg with a cor responding γ value of 0.96 transports only 210 mg per minute (30% difference). For the final pharmacokinetic model, TBW on V1 and TBW on the γ factor were found to be the most predictive covariates for the reduced cefazolin distribution observed in morbidly obese patients. The slight overestimation of lower subcutaneous cefazolin concentra tions in morbidly obese patient can be explained by the relatively high interindividual variability observed for cefazolin subcutaneous concentrations. While the model under predicts concentrations at 230 minutes after dosing for some morbidly obese patients, for others it overestimates other concentrations at the same time after dose for others.
In contrast to the differences observed in cefazolin distribution between morbidly obese and non obese patients, we found that cefazolin saturable protein binding was similar for both patient groups. Plasma albumin concentrations were not measured in this study and may have been a covariate for maximal binding capacity (B max ). However, for this parameter interindividual variability was relatively small (11.6%) and thus the influence of difference in albumin concentration on cefazolin pharmacokinetics is as sumed to be limited. Furthermore, the extent of saturable protein binding corresponded to earlier reports in nonobese and morbidly obese patients 16, 2728 , and estimated B max and K d values correspond to values found in earlier studies in human plasma, in which B max was reported to be 438 μM and K d was 50 and 60.2 μM 2930 .
To determine the efficacy of prophylactic cefazolin, currently the time of unbound plasma cefazolin above the MIC (fT >MIC ) between opening and closure of the wound is used as the pharmacokinetic/pharmacodynamic (PK/PD) index. However, this is based on the assumption that cefazolin penetration from plasma to the ISF of the subcutane ous tissue is equal to 1 7 , whereas in this study it was found that cefazolin tissue distribu tion is lower than 1 for morbidly obese patients. This suggests that for morbidly obese patients ISF tissue concentrations rather than unbound plasma concentrations should be considered as the PK/PD index to target for cefazolin efficacy. Monte Carlo simula tions allowed evaluation of cefazolin ISF tissue concentrations in large simulated patient populations and indicated that a dose of 2 gram iv cefazolin given prior to incision will be sufficient to prevent wound infections with pathogens for which the MIC is 1 mg/L in a 120 minute surgical procedure. However, when higher MIC values apply (e.g. 2 or 4 mg/L) redosing may be required after 2 hours as the probability of attaining a target of 4 mg/L at 180 minutes post dose has dropped to 0.909 for morbidly obese as opposed to 0.995 for nonobese patients, while for a target of 2 mg/L the probability of target attain ment is 0.956 in morbidly obese versus 0.997 in nonobese patients at 240 minutes post dose (Table 3) . Alternatively, it is obvious that if surgery is prolonged beyond 4 hours, an extra dose is necessary even when an MIC of 1 mg/L is taken as the reference value.
The design of the current study allowed for a straight forward and extensive compari son of unbound cefazolin concentrations in both plasma and ISF of the subcutaneous adipose tissue in morbidly obese and nonobese patients undergoing laparoscopic gas tric surgery. In addition, it allowed for a quantitative analysis of the influence of morbid obesity on cefazolin distribution. Nevertheless, the current study has some limitations. Firstly, this study only included 15 patients, which may limit an accurate estimation of interindividual and residual variability of pharmacokinetic parameters, which in turn may prevent broad conclusions being drawn regarding cefazolin efficacy in morbidly obese patients. Also, extrapolation of this model to patients beyond the body weight ranges of these data should be exercised with caution. However, the data gathered in this study is rather unique both in terms of methods (rich data, semi simultaneous observations in ISF and plasma) and patients, and currently no other evidence about cefazolin efficacy in morbidly obese patients is available. Secondly, the ISF data from one morbidly obese patient was excluded from the pharmacokinetic analysis, because the ISF timeconcentration profile of this patient was highly deviating and outlying in comparison with the other morbidly obese patients in this study. This deviation may be explained by the relatively low microdialysis recovery ratio measured for this patient (13.6%, compared to a mean of 28.1% ± 7.9). Thirdly, it should be stated that the model developed here, slightly overestimates lower subcutaneous cefazolin concentrations in some of the morbidly obese patients. If the model had predicted these lower cefazolin ISF concentrations more accurately, the probability of target attainment results from the Monte Carlo simulation may have been even more disadvantageous for morbidly obese patients. Finally, it is assumed that these potential weaknesses do not explain the lower cefazolin tissue penetration found for morbidly obese patients in this study.
In conclusion, this study showed that cefazolin distribution to the ISF of the subcutane ous adipose tissue is reduced in morbidly obese versus nonobese patient, that cefazolin tissue distribution reduces with increasing body weight and that dose adjustments are required in this patient group. Results of the NPDE analysis. The first graph of each set of three graphs shows the histograms with the distribution of the NPDEs for cefazolin. The solid line depicts a normal distribution and the values below specify the mean and standard deviation of the observed NPDE distribution in the histograms. The distribution of NPDEs in (X) time and against the observed concentrations (predicted Y) are shown in the second and third graph of each set, respectively.
